Distribution of anti‐factor Xa activity in patients with nonvalvular atrial fibrillation receiving 15 mg dose of edoxaban-Reference-Cited by-同舟云学术

Distribution of anti‐factor Xa activity in patients with nonvalvular atrial fibrillation receiving 15 mg dose of edoxaban

Published:2024-08-27 Issue: Volume: Page:
ISSN:1880-4276
Container-title:Journal of Arrhythmia
language:en
Short-container-title:Journal of Arrhythmia

Author:

Hiramatsu Shotaro¹^ORCID,Osanai Hiroyuki²,Sakai Yuichiro²,Sogo Yoshiki²,Tanaka Yuki³,Matsumoto Hikari⁴,Miyamoto Shun⁵,Tagahara Kensuke⁴,Arai Kenji²,Watanabe Takashi²,Sakamoto Yusuke²^ORCID,Sakaguchi Teruhiro²,Oguchi Shioh²,Kanbara Takahiro²,Nakashima Yoshihito²,Asano Hiroshi²,Ajioka Masayoshi²

Affiliation:

1. Department of Cardiology Gifu Prefectural Tajimi Hospital Tajimi Gifu Japan

2. Department of Cardiology Tosei General Hospital Seto Aichi Japan

3. Department of Cardiology Kumiai Kosei Hospital Takayama Gifu Japan

4. Department of Cardiology Nagoya University Hospital Nagoya Aichi Japan

5. Department of Cardiology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Aichi Japan

Abstract

AbstractBackgroundThe distribution of anti‐factor Xa activity (AXA) in patients with nonvalvular atrial fibrillation (NVAF) taking edoxaban 15 mg has not been fully elucidated.Methods and ResultsThe trough and peak AXA were measured in 19 NVAF patients taking edoxaban 15 mg. We compared these results with those in patients taking edoxaban 30 mg. The peak AXA differed significantly between the 15 mg and the 30 mg groups (0.74 ± 0.40 IU/mL vs. 1.25 ± 0.48 IU/mL, respectively; p < 0.0001).ConclusionsPeak but trough AXA in the patients receiving edoxaban 15 mg were significantly lower than those in patients receiving edoxaban 30 mg.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/joa3.13139

Reference16 articles.

1. Edoxaban versus Warfarin in Patients with Atrial Fibrillation

2. Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation

3. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013)

4. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation

5. Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants